Table 3 Patient characteristics of tumor patients with SCNA positive and SCNA negative cfDNA profiles in next-generation sequencing
|  | CSF SCNA positive cancer patients (n = 10) | CSF SCNA negative cancer patients (n = 2) |
|---|---|---|
Primary CNS tumors % (n) | 70 (7) | 100 (2) |
 Glioma % (n) | 50 (5) | 50 (1) |
 CNS-DLBCL % (n) | 20 (2) | 0 (0) |
 Meningeal melanocytoma % (n) | 0 (0) | 50 (1) |
Secondary CNS tumors % (n) | 30 (3) | 0 (0) |
 Secondary CNS lymphoma % (n) | 20 (2) | 0 (0) |
 Brain Metastases % (n) | 10 (1) | 0 (0) |
LMD % (n) | Â | Â |
 MRI-suspected % (n) | 30 (3) | 50 (1) |
 CSF cytology positive % (n) | 50 (5) | 0 (0) |